First-ever systemically administered CRISPR therapy paves way for revolution in treatment of genetic disorders
Intellia Therapeutics and Regeneron Pharmaceuticals have presented positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.